SEC 8-K and 6-K filings classified by Claude with reasoning, plus Form 4 insider transactions. Ingested from EDGAR’s filing stream in near-real time, reconciled overnight.
Open-market buys and sells only — the deliberate trades. Zero here doesn’t mean no filings: grants, option exercises and tax withholding (below) are compensation, not market trades.
| Insider | Role | Date | Transaction | Shares | Value |
|---|---|---|---|---|---|
| Krikorian Lazarus | SVP & Chief Accounting Officer | 2026-09-01 | Open-market sell 10b5-1 | 985 | $321K |
| Campbell Elizabeth S | Executive Vice President | 2026-08-24 | Open-market sell | 11300 | $3.7M |
| Cooper Ellen | Director | 2026-07-31 | Grant/award | 97 | $30K |
| NALLY DENNIS M | Director | 2026-07-31 | Grant/award | 113 | $35K |
| Tyler Lauren M | Director | 2026-07-31 | Grant/award | 97 | $30K |
| Battaglia Silvana | Executive Vice President | 2026-06-30 | Grant/award | 58 | $14K |
| Campbell Elizabeth S | Executive Vice President | 2026-06-30 | Grant/award | 50 | $12K |
| Tyler Lauren M | Director | 2026-06-22 | Open-market buy | 550 | $149K |
| DURCAN DERMOT MARK | Director | 2026-06-18 | Open-market buy | 4000 | $1.1M |
| DURCAN DERMOT MARK | Director | 2026-05-28 | Open-market buy | 4000 | $1.1M |
| Cooper Ellen | Director | 2026-05-01 | Grant/award | 99 | $30K |
| NALLY DENNIS M | Director | 2026-05-01 | Grant/award | 116 | $35K |
| Tyler Lauren M | Director | 2026-05-01 | Grant/award | 99 | $30K |
| Battaglia Silvana | Executive Vice President | 2026-03-11 | Option exercise | 8415 | $0 |
| Battaglia Silvana | Executive Vice President | 2026-03-11 | Tax withholding | 3673 | $1.3M |
| Campbell Elizabeth S | Executive Vice President | 2026-03-11 | Option exercise | 12623 | $0 |
| Campbell Elizabeth S | Executive Vice President | 2026-03-11 | Tax withholding | 5842 | $2.0M |
| Cleary James F | Chief Financial Officer | 2026-03-11 | Option exercise | 12623 | $0 |
| Cleary James F | Chief Financial Officer | 2026-03-11 | Tax withholding | 5409 | $1.9M |
| Baumann Werner | Director | 2026-03-05 | Grant/award | 557 | $200K |
Fiscal period ending 2025-09-30 versus 2024-09-30 — view filing on EDGAR →
A $723.9M goodwill impairment (full PharmaLex write-off) and the Sycamore Partners acquisition of WBA — the company's largest customer at 38% of receivables — together represent acute solvency and revenue-continuity threats. Risk worsening is pervasive, spanning M&A/strategic, regulatory, competitive, macro/tariff, and cybersecurity themes simultaneously. The single debt-structure easing (resolution of WBA's variable prepaid forward) is immaterial against this breadth of escalation.
9 company-specific · 1 eased/removed · 7 common-mode
Additional $723.9M goodwill impairment recorded; PharmaLex weakness persists and worsened, requiring full remaining goodwill write-off.
Our goodwill or long-lived assets may become impaired, which may require us to record a significant charge to earnings in accordance with generally accepted accounting principles. U.S. generally…
WBA acquired by Sycamore Partners; new owners may restructure operations, accelerate store closures (1,200 stores), and seek changes to distribution agreements. Material new uncertainty regarding contract continuity and relationship stability.
The anticipated ongoing benefits of our relationship with Walgreens and Boots may not be realized. On August 28, 2025, Sycamore Partners, a private equity firm, acquired Walgreens Boots Alliance…
New disclosure of Executive Order 14297 and MFN pricing/DTC mechanisms that could bypass traditional supply chain intermediaries, creating material revenue and margin risk.
Industry and Economic Risks Our results of operations could be adversely impacted by manufacturer pricing changes. Our contractual arrangements with pharmaceutical manufacturers for the purchase of…
Walgreens/Boots concentration increased from 26% to 25% revenue but now represents 38% of accounts receivable, signaling heightened collection and credit risk exposure.
Business and Operational Risks Our revenue, financial position, results of operations, and cash flows may suffer upon the loss, or renewal at less favorable terms, of a key customer or group…
RCA acquisition completed; new specific regulatory risks disclosed (MSO regulations, billing/coding, corporate practice of medicine, FDA clinical trial obligations) and integration complexity materially expanded.
Our results of operations and financial position may be adversely affected if we acquire or invest in businesses that do not perform as we expect or that are difficult for us to integrate. As part of…
Added explicit supplier credit risk and supply chain disruption exposure. Identified largest customer by name (Walgreens/Boots/Evernorth). Expanded risk scope materially.
Our revenue and results of operations may suffer upon the bankruptcy, insolvency, or other credit failure of a significant customer or supplier. Most of our customers buy pharmaceuticals and other…
Expanded disclosure of divestiture risks: added third-party approval delays, customer/personnel relationship damage, post-divestiture obligations, and non-compete restrictions. Materially broadens risk scope.
Our business and results of operations may be adversely affected if we fail to manage and complete divestitures. We regularly evaluate our portfolio to determine whether an asset or business may no…
Added exposure to customs/tariff litigation and third-party business disputes. Expands qui tam scope to include customs violations and misrepresentations to CBP.
Our business, results of operations, and cash flows could be adversely affected by legal proceedings. Due to the nature of our operations, which we conduct through a variety of businesses, including…
New disclosure of M&A integration risk: acquisitions may lack effective FCPA/anti-corruption controls, escalating compliance exposure post-acquisition.
Violations of anti-bribery, anti-corruption, and/or international trade laws that we are subject to could have a material adverse effect on our business, financial position, and results of…
Removal of material risk: WBA's variable prepaid forward transactions on 20M shares and associated stock price pressure risk have been resolved or closed, reducing capital structure uncertainty.
The closing of the variable prepaid forward transactions concerning our common stock by WBA could adversely affect prevailing market prices of our common stock. WBA has the right, but not the…
New EU pharmaceutical package and Critical Medicines Act impose mandatory stockpiling, stringent notification duties, and shortage prevention plans with material compliance costs and operational complexity.
Litigation and Regulatory Risks Increasing governmental efforts to regulate the pharmaceutical supply chain may increase our costs and reduce our profitability. The healthcare industry in the U.S.…
New material regulatory risks: OBBBA (July 2025) with Medicaid work requirements and payment cuts; EU HTA Regulation (Jan 2025); CMS proposed rule accelerating 340B refund recapture and tightening BFSF exemptions for ASP calculations.
Legal, regulatory, and legislative changes with respect to coverage, reimbursement, pricing, and contracting may adversely affect our business and results of operations, including through declining…
New AI-specific regulatory risks added: EU AI Act compliance, fines, and operational changes required. Escalates cybersecurity risk profile materially.
Any actual or perceived failure to adequately protect proprietary business information or personal data could result in claims of liability against us, damage our reputation or otherwise materially…
Tariff risk substantially expanded: now specifically names fentanyl, reciprocal, secondary tariffs on India/Brazil, Section 232 pharma tariffs, and counter-tariffs. Adds packaging/materials costs. Materially more concrete and detailed.
We face geopolitical and other risks associated with our international operations, which could materially adversely impact our financial position, results of operations, and cash flows. We conduct…
Risk escalated: added AI-enabled cyber threats, industry targeting disclosure, cloud dependency expansion, and implementation cost/timeline risks for new systems.
The loss or disruption of information systems could disrupt our operations and have a material adverse effect on our business. Our businesses rely on sophisticated information systems and AI to…
Added specific EU directives (CSRD, CSDDD), expanded compliance obligations, litigation/audit/investigation risks, and stakeholder action consequences. Escalates regulatory and operational exposure.
Any actual or perceived failure to protect our reputation could have a material adverse effect on our business and operations. We believe that maintaining and enhancing our reputation is critical to…
Added explicit mention of sanctions and tariffs as distinct trade risks; added "incurred increased costs" as consequence. Reflects escalated geopolitical risk disclosure.
We have been and may in the future be adversely impacted by events outside of our control. We have been and may in the future be adversely affected by events outside of our control, including…
Dr. Lorence H. Kim resigned from the Board of Directors effective immediately on August 13, 2026, due to his appointment as Chief Financial Officer of Commonwealth Fusion Systems, Inc. This is a clear departure of a director from the registrant's board, making it a material executive departure event that would affect a reasonable investor's assessment of board composition and governance.
View raw filing on EDGAR →Cencora discloses that beginning July 1, 2026, certain Walgreens volume outside the prime vendor agreement "began moving outside the Company," while reaffirming its adjusted diluted EPS guidance. This is a material operational event involving loss of customer volume from a major customer (Walgreens), though the company characterizes it as "fully contemplated" and notes the prime vendor agreement remains unchanged. The disclosure is operational in nature (customer volume shift) rather than fitting a specific category like M&A, impairment, or covenant breach.
View raw filing on EDGAR →Cencora amended and restated its multi-currency revolving credit facility on July 31, 2026, increasing aggregate commitments from $5.5 billion to $7.0 billion and extending maturity to July 2031. The company also amended its receivables securitization facility, restructuring its size and accordion features.
View raw filing on EDGAR →Cencora issued a news release on August 5, 2026 announcing fiscal Q3 2026 earnings with revenue of $84.8 billion (5.1% YoY growth), GAAP diluted EPS of $3.94, and adjusted diluted EPS of $4.48 (12.0% increase), while raising full-year fiscal 2026 adjusted diluted EPS guidance to $17.75–$17.95.
View raw filing on EDGAR →Samantha L. Hammock was appointed as Executive Vice President and Chief Human Resources Officer, effective July 13, 2026, succeeding Silvana Battaglia who retired from the role effective July 12, 2026. Ms. Hammock joins from Verizon, bringing external leadership to the company's human resources function.
View raw filing on EDGAR →Eva C. Boratto has been appointed Executive Vice President and Chief Financial Officer of Cencora, Inc., effective June 29, 2026, succeeding retiring CFO James F. Cleary. The appointment includes compensatory arrangements including a $1,000,000 base salary, 100% annual bonus target, $2,000,000 sign-on bonus, and $6,000,000 RSU award.
View raw filing on EDGAR →